Abiraterone Acetate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 200030

CAS#: 154229-18-2 (Abiraterone Acetate)

Description: Abiraterone acetate is an FDA approved drug, and is an orally active acetate ester of the steroidal compound abiraterone with antiandrogen activity. Abiraterone acetate was approved by the U.S. Food and Drug Administration (FDA) in April 2011. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. FDA Approval this drug in May 2011.


Price and Availability

Size
Price

2g
USD 150
100g
USD 2150
2kg
USD 12650
Size
Price

10g
USD 450
200g
USD 3450
Size
Price

50g
USD 1250
500g
USD 4850

Abiraterone Acetate purity > 98% is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 250g may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 200030
Name: Abiraterone Acetate
CAS#: 154229-18-2 (Abiraterone Acetate)
Chemical Formula: C26H33NO2
Exact Mass: 391.25113
Molecular Weight: 391.54
Elemental Analysis: C, 79.76; H, 8.50; N, 3.58; O, 8.17


Related CAS #: 154229-18-2 (Abiraterone Acetate)   154229-19-3 (Abiraterone)    

Synonym: CB 7630 ; CB-7630; CB7630; Abiraterone Acetate; brand name: Zytiga.

IUPAC/Chemical Name: [(3S,10R,13S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate

InChi Key: UVIQSJCZCSLXRZ-HMMZIKKISA-N

InChi Code: InChI=1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21?,23?,24?,25-,26+/m0/s1

SMILES Code: CC(O[C@H]1CC[C@]2(C)C3CC[C@]4(C)C(C5=CC=CN=C5)=CCC4C3CC=C2C1)=O


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>10 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

ZYTIGA™ (abiraterone acetate) received FDA Approval  in May 2011 for Treatment of Metastatic Prostate Cancer After Priority Review; First Once-Daily, Oral Treatment for Metastatic Prostate Cancer Inhibits Androgen Production. ZYTIGA™ (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.
 
 
 


References

1: Grist E, Attard G. The development of abiraterone acetate for castration-resistant prostate cancer. Urol Oncol. 2015 Jun;33(6):289-294. doi: 10.1016/j.urolonc.2015.03.021. Review. PubMed PMID: 26025264.

2: Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series. Clin Genitourin Cancer. 2015 Jun;13(3):193-198. doi: 10.1016/j.clgc.2014.10.006. Epub 2014 Nov 7. Review. PubMed PMID: 25466676.

3: Giacinti S, Bassanelli M, Aschelter AM, Milano A, Roberto M, Marchetti P. Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer Res. 2014 Nov;34(11):6265-9. Review. PubMed PMID: 25368223.

4: Zobniw CM, Causebrook A, Fong MK. Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014 Aug 5;6:97-105. doi: 10.2147/RRU.S29003. eCollection 2014. Review. PubMed PMID: 25157341; PubMed Central PMCID: PMC4128838.

5: Francini E, Petrioli R, Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther. 2014 Oct;14(10):1135-40. doi: 10.1586/14737140.2014.949677. Epub 2014 Aug 19. Review. PubMed PMID: 25135334.

6: Woo HH, Begbie S, Gogna K, Mainwaring PN, Murphy DG, Parnis F, Steer C, Davis ID. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice. Asia Pac J Clin Oncol. 2014 Sep;10(3):228-36. doi: 10.1111/ajco.12264. Epub 2014 Aug 17. Review. PubMed PMID: 25132163.

7: Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer. 2014 Oct;5(5):265-73. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22. Review. PubMed PMID: 25048254; PubMed Central PMCID: PMC4167475.

8: Boissier E, Loriot Y, Vignot S, Massard C. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French. PubMed PMID: 24793632.

9: Mostaghel EA, Lin DW. Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):57-63. Review. PubMed PMID: 24775725; PubMed Central PMCID: PMC4139288.

10: Zhou ZR, Liu SX, Zhang TS, Xia J, Li B. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(3):1313-20. Review. PubMed PMID: 24606458.